CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.68 USD | +1.38% |
|
-4.42% | -35.78% |
| Apr. 05 | Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday | MT |
| Apr. 04 | Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients | MT |
Chart calendar Caribou Biosciences, Inc.
e5743afd91624ee9a0a1f296f70fbc._dE_tXW4VTId8PyIWUu6V_gkGh711-q4sqwjKvEDhxw.lbZbhgTUB1dfs6bqbSGDFpFqYkq5h9qJ5MdHRYBIslOWknzvIfwYfkKFnw~f6c09e3df2203672b2505ba89392c86e
Upcoming events on Caribou Biosciences, Inc.
Past events on Caribou Biosciences, Inc.
| 2024-04-09 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: 6323 |
| 2024-04-04 05:00 pm | CB-010 Clinical Development Expansion Call |
| 2024-03-26 11:30 am | H.C. Wainwright Cell Therapy Virtual Conference |
| 2024-03-12 | Barclays Global Healthcare Conference |
| 2024-03-12 01:40 pm | Leerink Partners Global Biopharma Conference |
| 2024-03-11 04:05 pm | Q4 2023 Earnings Release |
| 2024-02-21 12:00 pm | Citi Oncology Leadership Summit |
| 2024-01-11 02:15 pm | JPMorgan Healthcare Conference |
| 2023-11-30 10:00 am | Evercore ISI HealthCONx Conference |
| 2023-11-15 07:30 am | Jefferies London Healthcare Conference |
| 2023-11-08 | Truist Securities Healthcare Conference |
| 2023-11-07 04:00 pm | Q3 2023 Earnings Release |
| 2023-10-09 | Cell & Gene Meeting on the Mesa Conference |
| 2023-09-28 12:05 pm | Cantor Global Healthcare Conference |
| 2023-09-27 08:00 am | Jefferies Cell & Genetic Medicine Summit |
| 2023-09-10 | Morgan Stanley Global Healthcare Conference |
| 2023-09-07 08:00 am | Wells Fargo Healthcare Conference |
| 2023-09-05 | Citi BioPharma Conference |
| 2023-08-08 04:00 pm | Q2 2023 Earnings Release |
| 2023-07-13 04:30 pm | ANTLER Phase 1 Trial Results Update Call |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 9,60 10,9 -12.32% | 13,9 13,4 3.6% | 34,5 34,9 -1.16% | 9,54 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -66,0 -67,4 2.05% | -105 -106 0.93% | -113 -113 0.6% | -175 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -67,0 -66,6 -0.63% | -106 -106 -0.35% | -116 -114 -1.52% | -172 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -66,6 -66,6 0.03% | -99,4 -103 3.34% | -102 -102 0.39% | -162 |
|
Net income Million USD | Released Forecast Spread | -34,3 | -66,9 -66,9 -0.08% | -99,4 -102 2.92% | -102 -102 -0.47% | -157 |
|
EPS USD | Released Forecast Spread | -7,30 | -2,11 -2,14 1.41% | -1,64 -1,69 3.01% | -1,38 -1,39 0.9% | -1,79 |
| Announcement Date | 07/05/21 | 21/03/22 | 09/03/23 | 11/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,56 4,19 -38.88% | 2,66 3,20 -16.75% | 4,19 2,86 46.57% | 3,30 3,70 -10.73% | 3,69 3,07 20.34% | 3,50 3,15 11.17% | 3,76 3,07 22.39% | 23,7 2,60 810.08% | 3,56 4,61 -22.88% | 2,42 | 2,48 | 2,35 | 2,33 | 5,00 |
|
EBITDA Million USD | Released Forecast Spread | -36,7 -38,1 3.62% | -42,1 | -44,1 | -46,2 | -48,4 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -20,4 -21,8 6.38% | -20,9 -21,1 1.21% | -28,4 -21,7 -30.93% | -26,5 -30,7 13.49% | -30,6 -29,5 -3.59% | -31,1 -31,4 0.96% | -32,9 -33,8 2.77% | -14,6 -34,7 57.85% | -37,4 -35,8 -4.48% | -39,9 | -42,7 | -45,4 | -47,6 | -51,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -18,2 -21,0 13.57% | -19,1 -20,4 6.3% | -26,7 -20,8 -28.1% | -26,6 -29,8 10.52% | -26,9 -29,0 7.23% | -28,0 -30,7 8.63% | -29,5 -32,3 8.55% | -10,0 -32,9 69.6% | -34,3 -32,9 -4.15% | -37,3 | -40,4 | -43,2 | -45,6 | -49,0 |
|
Net income Million USD | Released Forecast Spread | -18,5 -20,8 11.14% | -19,1 -20,6 7.39% | -26,7 -21,8 -22.5% | -26,6 -29,2 8.63% | -27,0 -28,1 4.07% | -28,0 -29,3 4.26% | -29,5 -30,5 3.35% | -10,0 -31,2 67.91% | -34,5 -32,0 -7.75% | -36,4 | -38,9 | -41,0 | -43,1 | -49,0 |
|
EPS USD | Released Forecast Spread | -0,31 -0,36 14.19% | -0,32 -0,35 7.25% | -0,44 -0,36 -21.14% | -0,44 -0,48 8.9% | -0,44 -0,46 4.67% | -0,46 -0,49 5.59% | -0,48 -0,49 3% | -0,12 -0,42 71.17% | -0,39 -0,39 -0.74% | -0,41 | -0,43 | -0,46 | -0,47 | -0,49 |
| Announcement Date | 21/03/22 | 09/05/22 | 09/08/22 | 08/11/22 | 09/03/23 | 09/05/23 | 08/08/23 | 07/11/23 | 11/03/24 | - | - | - | - | - |
| Today 06:30 am | MODERNA, INC.: Q1 2024 Earnings Release |
| Today 07:00 am | BLUEPRINT MEDICINES CORPORATION: Q1 2024 Earnings Release |
| Today 07:00 am | KYMERA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| Today 07:00 am | IQVIA HOLDINGS INC.: Q1 2024 Earnings Release |
| Today 08:00 am | ALNYLAM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 2024-05-05 | REVOLUTION MEDICINES, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-05 | SYNDAX PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | FORTREA HOLDINGS INC.: Q1 2024 Earnings Release |
| 2024-05-06 | VERVE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | OLEMA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Caribou Biosciences, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CRBU Stock
- Calendar Caribou Biosciences, Inc.
